NEW YORK (GenomeWeb News) – Genetic Technologies today said that a US federal court has denied a motion by Agilent Technologies to dismiss a lawsuit in which GTG accused Agilent of infringing its primary non-coding DNA patent.

Agilent had filed its motion for dismissal, saying US Patent No. 5,612,179 held by GTG covered natural phenomena or laws of nature and therefore could not be patented. The US District Court for the Northern District of California issued an order last week denying Agilent's request, GTG said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.